专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010081856A1 PULMONARY ADMINISTRATION OF IMMUNOGLOBULIN SINGLE VARIABLE DOMAINS AND CONSTRUCTS THEREOF 审中-公开
标题翻译：免疫球蛋白单链可变域的构建及其构建
公开(公告)号：WO2010081856A1
公开(公告)日：2010-07-22
申请号：PCT/EP2010/050414
申请日：2010-01-14
申请人： ABLYNX NV , BOUCHE, Marie-Paule Lucienne Armanda , VANLANDSCHOOT, Peter , SABLON, Erwin , DEPLA, Erik , DE BUCK, Stefan , SAELENS, Xavier , SCHEPENS, Bert
发明人： BOUCHE, Marie-Paule Lucienne Armanda , VANLANDSCHOOT, Peter , SABLON, Erwin , DEPLA, Erik , DE BUCK, Stefan , SAELENS, Xavier , SCHEPENS, Bert
IPC分类号： C07K16/10 , C07K16/18 , A61P31/12
CPC分类号： C07K16/1027 , A61K2039/505 , C07K16/1018 , C07K16/18 , C07K2317/22 , C07K2317/31 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/569
摘要： The present invention relates to a method wherein an immunoglobulin single variable domain (such as a Nanobody) and/or construct thereof are absorbed in pulmonary tissue. More particularly, the invention provides systemic delivery of an immunoglobulin single variable domain and/or construct thereof via the pulmonary route.
摘要翻译：本发明涉及其中免疫球蛋白单可变结构域（例如纳米抗体）和/或其构建体在肺组织中被吸收的方法。更具体地，本发明提供了经由肺途径的免疫球蛋白单可变结构域和/或其构建体的全身递送。

2. 发明申请

WO2002086100A3 EXPRESSION OF CORE-GLYCOSYLATED HCV ENVELOPE PROTEINS IN YEAST 审中-公开
公开(公告)号：WO2002086100A3
公开(公告)日：2002-10-31
申请号：PCT/BE2002/000063
申请日：2002-04-24
申请人： INNOGENETICS N.V. , BOSMAN, Alfons , DEPLA, Erik , DESCHAMPS, Geert , SABLON, Erwin , SAMSON, Isabelle , VAN BROEKHOVEN, Annie , HAELEWYN, Joost
发明人： BOSMAN, Alfons , DEPLA, Erik , DESCHAMPS, Geert , SABLON, Erwin , SAMSON, Isabelle , VAN BROEKHOVEN, Annie , HAELEWYN, Joost
IPC分类号： C12N1/16
摘要： The present invention relates to the general field of recombinant protein expression, purification of recombinant proteins, diagnosis of HCV infection, prophylactic treatment against HCV infection and to the prognosing/monitoring of the clinical efficiency of treatment of an individual with chronic hepatitis, or the prognosing/ monitoring of the natural disease. In particular, the present invention relates to the use of yeast, i.e. Hansenula or Saccharomyces glycosylation minus strains, for the efficient expression of HCV envelope proteins that are core-glycosylated, purification methods for these proteins, and the use in various applications, such as the use in diagnosis, prophylaxis or therapy of HCV envelope proteins purified according to the present invention.

3. 发明申请

WO2002085932A2 CONSTRUCTS AND METHODS FOR EXPRESSION OF RECOMBINANT HCV ENVELOPE PROTEINS 审中-公开
标题翻译：用于表达重组HCV包膜蛋白的构建体和方法
公开(公告)号：WO2002085932A2
公开(公告)日：2002-10-31
申请号：PCT/BE2002/000062
申请日：2002-04-24
申请人： INNOGENETICS N.V. , SABLON, Erwin , VAN BROEKHOVEN, Annie , BOSMAN, Alfons , DEPLA, Erik , DESCHAMPS, Geert
发明人： SABLON, Erwin , VAN BROEKHOVEN, Annie , BOSMAN, Alfons , DEPLA, Erik , DESCHAMPS, Geert
IPC分类号： C07K14/18
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/5258 , C07K2319/02 , C07K2319/50 , C12N7/00 , C12N2770/24222 , C12N2770/24223
摘要： The current invention relates to vectors and methods for efficient expression of HCV envelope proteins in eukaryotic cells. More particularly said vectors comprise the coding sequence for an avian lysozyme signal peptide or a functional equivalent thereof joined to a HCV envelope protein or a part thereof. Said avian lysozyme signal peptide is efficiently removed when the protein comprising said avian lysozyme signal peptide joined to a HCV envelope protein or a part thereof is expressed in a eukaryotic cell. Suitable eukaryotic cells include yeast cells such as Saccharomyces or Hansenula cells.
摘要翻译：本发明涉及在真核细胞中有效表达HCV包膜蛋白的载体和方法。更具体地说，所述载体包含与HCV包膜蛋白或其一部分连接的禽溶菌酶信号肽或其功能等同物的编码序列。当包含与HCV包膜蛋白或其部分连接的禽类溶菌酶信号肽的蛋白质在真核细胞中表达时，所述禽溶菌酶信号肽被有效去除。合适的真核细胞包括酵母细胞如酵母或汉逊酵母细胞。

4. 发明申请

WO2002086101A2 CORE-GLYCOSYLATED HCV ENVELOPE PROTEINS 审中-公开
标题翻译：核心糖蛋白HCV包膜蛋白
公开(公告)号：WO2002086101A2
公开(公告)日：2002-10-31
申请号：PCT/BE2002/000064
申请日：2002-04-24
申请人： INNOGENETICS N.V. , DEPLA, Erik , BOSMAN, Alfons , DESCHAMPS, Geert , SABLON, Erwin , SUCKOW, Manfred , SAMSON, Isabelle , VERHEYDEN, Gert
发明人： DEPLA, Erik , BOSMAN, Alfons , DESCHAMPS, Geert , SABLON, Erwin , SUCKOW, Manfred , SAMSON, Isabelle , VERHEYDEN, Gert
IPC分类号： C12N1/16
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/5258 , C07K2319/02 , C07K2319/50 , C12N7/00 , C12N2770/24222 , C12N2770/24223
摘要： The current invention relates to HCV envelope proteins or parts thereof which are the product of expression in eukaryotic cells. More particularly said HCV envelope proteins are characterized in that on average up to 80 % of their N-glycosylation sites are core-glycosylated. Of these N-glycosylated sites more than 70 % are glycosylated with an oligomannose containing 8 to 10 mannoses. Furthermore, the ratio of the oligomannoses with structure Man(7)-GlcNAc(2) over the oligomannose with structure Man(8)-GlcNAc(2) is less than or equal to 0.45. Less than 10 % of the oligomannoses is terminated with an α1,3 linked mannose. The HCV envelope proteins of the invention are particularly suited for diagnostic, prophylactic and therapeutic purposes. A suitable eukaryotic cell for production of the HCV envelope proteins of the invention is a Hansenula cell.
摘要翻译：本发明涉及作为在真核细胞中表达的产物的HCV包膜蛋白或其部分。更具体地说，HCV包膜蛋白的特征在于平均高达80％的N-糖基化位点是核糖基化的。在这些N-糖基化位点中，超过70％的糖苷化与含有8至10个甘露糖的寡甘露糖糖基化。此外，结构Man（7）-GlcNAc（2）的寡甘露糖与结构Man（8）-GlcNAc（2）的寡甘露糖的比例小于或等于0.45。少于10％的寡甘露聚糖用α1,3连接的甘露糖终止。本发明的HCV包膜蛋白特别适用于诊断，预防和治疗目的。用于生产本发明的HCV包膜蛋白的合适的真核细胞是Hansenula细胞。

5. 发明申请

WO2002086100A2 EXPRESSION OF CORE-GLYCOSYLATED HCV ENVELOPE PROTEINS IN YEAST 审中-公开
标题翻译：核糖核酸乙肝病毒包膜蛋白在YEAST中的表达
公开(公告)号：WO2002086100A2
公开(公告)日：2002-10-31
申请号：PCT/BE2002/000063
申请日：2002-04-24
申请人： INNOGENETICS N.V. , BOSMAN, Alfons , DEPLA, Erik , DESCHAMPS, Geert , SABLON, Erwin , SAMSON, Isabelle , VAN BROEKHOVEN, Annie , HAELEWYN, Joost
发明人： BOSMAN, Alfons , DEPLA, Erik , DESCHAMPS, Geert , SABLON, Erwin , SAMSON, Isabelle , VAN BROEKHOVEN, Annie , HAELEWYN, Joost
IPC分类号： C12N1/16
CPC分类号： C07K14/005 , A61K38/00 , A61K39/00 , A61K2039/5258 , C07K2319/02 , C07K2319/50 , C12N7/00 , C12N2770/24222 , C12N2770/24223
摘要： The present invention relates to the general field of recombinant protein expression, purification of recombinant proteins, diagnosis of HCV infection, prophylactic treatment against HCV infection and to the prognosing/monitoring of the clinical efficiency of treatment of an individual with chronic hepatitis, or the prognosing/ monitoring of the natural disease. In particular, the present invention relates to the use of yeast, i.e. Hansenula or Saccharomyces glycosylation minus strains, for the efficient expression of HCV envelope proteins that are core-glycosylated, purification methods for these proteins, and the use in various applications, such as the use in diagnosis, prophylaxis or therapy of HCV envelope proteins purified according to the present invention.
摘要翻译：本发明涉及重组蛋白表达的一般领域，重组蛋白的纯化，HCV感染的诊断，HCV感染的预防性治疗以及慢性肝炎个体治疗的临床效果的预测/监测，或预后 /监测自然病。特别地，本发明涉及酵母，即汉逊酵母或酵母糖基化减去菌株，用于有效表达核糖糖基化的HCV包膜蛋白，这些蛋白质的纯化方法，以及在各种应用中的用途，例如用于诊断，预防或治疗根据本发明纯化的HCV包膜蛋白。

6. 发明申请

WO2003020970A3 NEW HEPATITIS C VIRUS GENOTYPE, AND ITS USE AS PROPHYLACTIC, THERAPEUTIC AND DIAGNOSTIC AGENT 审中-公开
公开(公告)号：WO2003020970A3
公开(公告)日：2003-03-13
申请号：PCT/EP2002/009731
申请日：2002-08-30
申请人： INNOGENETICS N.V. , SABLON, Erwin , VAN DOORN, Leen-Jan , QUINT, Wim
发明人： SABLON, Erwin , VAN DOORN, Leen-Jan , QUINT, Wim
IPC分类号： C07K14/18
摘要： The present invention relates to genomic nucleotide sequences and amino acid sequences corresponding to the non-coding and coding region of a new type of HCV. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes sequences. Particularly, the present invention relates to said new HCV type sequences; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the 5' NCR, Core, the E1 and the NS5 regions of the new HCV type. These new HCV sequences are useful to diagnose the presence of HCV type genotypes or serotypes in a biological sample. Moreover, the availability of these new type-specific sequences can increase the overall sensitivity of HCV detection and should also prove to be useful for prophylactic and therapeutic purposes.

7. 发明申请

WO2008046922A2 METHODOLOGY FOR ANAYSIS OF SEQUENCE VARIATIONS WITHIN THE HCV NS5B GENOMIC REGION 审中-公开
标题翻译：用于分析HCV NS5B基因组区域中序列变异的方法
公开(公告)号：WO2008046922A2
公开(公告)日：2008-04-24
申请号：PCT/EP2007/061241
申请日：2007-10-19
申请人： INNOGENETICS N.V. , SABLON, Erwin , LIBBRECHT, Evelien
发明人： SABLON, Erwin , LIBBRECHT, Evelien
IPC分类号： C12Q1/70
CPC分类号： C12Q1/707 , C12Q2600/156
摘要： The current invention relates to a standardized method for amplification o f an HCV NS5B nucleic acid fragment of any one of HCV genotypes 1 to 6 as a tool for analysis of sequence variations that may be correlated with HCV drug resistance.
摘要翻译：本发明涉及用于扩增HCV基因型1至6中任一HCV HCV NS5B核酸片段的标准方法，作为用于分析与HCV耐药性相关的序列变异的工具。

8. 发明申请

WO2008046923A2 METHODOLOGY FOR ANALYSIS OF SEQUENCE VARIATIONS WITHIN THE HCV NS3/4A GENOMIC REGION 审中-公开
标题翻译：用于分析HCV NS3 / 4A基因组区域中序列变异的方法
公开(公告)号：WO2008046923A2
公开(公告)日：2008-04-24
申请号：PCT/EP2007/061242
申请日：2007-10-19
申请人： INNOGENETICS N.V. , SABLON, Erwin , LIBBRECHT, Evelien
发明人： SABLON, Erwin , LIBBRECHT, Evelien
IPC分类号： C12Q1/70
CPC分类号： C12Q1/707
摘要： The current invention relates to a standardized method for amplification o f an HCV NS3/4A or NS3 nucleic acid fragment of any one of HCV genotypes 5 to 6 or HCV genotype 1 as a tool for analysis of sequence variations that may be correlated with 5 HCV drug resistance.
摘要翻译：本发明涉及用于扩增HCV基因型5至6或HCV基因型1中任一HCV HCV NS3 / 4A或NS3核酸片段的标准化方法，作为用于分析可能与5种HCV药物相关的序列变异的工具抵抗性。

9. 发明申请

WO2003020970A2 NEW HEPATITIS C VIRUS GENOTYPE, AND ITS USE AS PROPHYLACTIC, THERAPEUTIC AND DIAGNOSTIC AGENT 审中-公开
标题翻译：新型丙型肝炎病毒基因组及其用作预防，治疗和诊断代理
公开(公告)号：WO2003020970A2
公开(公告)日：2003-03-13
申请号：PCT/EP2002/009731
申请日：2002-08-30
申请人： INNOGENETICS N.V. , SABLON, Erwin , VAN DOORN, Leen-Jan , QUINT, Wim
发明人： SABLON, Erwin , VAN DOORN, Leen-Jan , QUINT, Wim
IPC分类号： C12Q1/68
CPC分类号： C12Q1/707
摘要： The present invention relates to genomic nucleotide sequences and amino acid sequences corresponding to the non-coding and coding region of a new type of HCV. The invention relates to new HCV types and subtypes sequences which are different from the known HCV types and subtypes sequences. Particularly, the present invention relates to said new HCV type sequences; a process for preparing them, and their use for diagnosis, prophylaxis and therapy. More particularly, the present invention provides new type-specific sequences of the 5' NCR, Core, the E1 and the NS5 regions of the new HCV type. These new HCV sequences are useful to diagnose the presence of HCV type genotypes or serotypes in a biological sample. Moreover, the availability of these new type-specific sequences can increase the overall sensitivity of HCV detection and should also prove to be useful for prophylactic and therapeutic purposes.
摘要翻译：本发明涉及对应于新型HCV的非编码区和编码区的基因组核苷酸序列和氨基酸序列。本发明涉及与已知的HCV类型和亚型序列不同的新的HCV类型和亚型序列。特别地，本发明涉及所述新型HCV型序列; 它们的制备过程及其在诊断，预防和治疗中的应用。更具体地说，本发明提供新HCV型5'NCR，核心，E1和NS5区域的新型特异性序列。这些新的HCV序列可用于诊断生物样品中HCV型基因型或血清型的存在。此外，这些新型特异性序列的可用性可以提高HCV检测的总体灵敏度，并且还应证明可用于预防和治疗目的。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式